Skip to content

Clinical trials

Delirium trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Delirium Clear all

879 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20034
20046
20059
200610
200713
200811
200913
201018
201125
201224
201335
201449
201545
201651
201756
201847
201966
202056
202164
202249
202363
202465
202538
202654

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed441
Unknown status164
Recruiting92
Terminated54
Not yet recruiting48
Withdrawn40
Active, not recruiting30
Suspended7
Enrolling by invitation3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Vanderbilt University Medical Center15
Charite University, Berlin, Germany14
Assistance Publique - Hôpitaux de Paris13
Peking University First Hospital11
Vanderbilt University11
Johns Hopkins University10
Beth Israel Deaconess Medical Center9
University Health Network, Toronto9
Ohio State University8
Indiana University7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Delirium879
Emergence Delirium105
Cognitive Dysfunction104
Critical Illness76
Dementia55
Confusion45
Pain35
Psychomotor Agitation30
Postoperative Cognitive Complications28
Anxiety Disorders26

Trials

Showing 51 to 75 of 879. Each trial links to its page on Pharma Observatory.

779 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.